Where does a good treatment get stuck? Three UK startups, three answers

A treatment can stall at the lab, at the trial stage or at the bedside. These three UK startups each work on one of those stages.

Stuck at the lab: a drug dropped for safety reasons.

Ignota Labs in Cambridge picks up candidates that were halted over toxicity. Its platform uses deep learning to work out why a compound is toxic, so the molecule can be reworked instead of binned. It closed a $6.9m seed round in 2025.

Stuck in biology: damage we can’t yet stop.

LinkGevity is working on necrosis inhibitors it calls Anti-Necrotics. Its candidate for acute kidney injury is being prepared for Phase 2. The company is based at the Babraham Research Campus and was founded by two sisters in 2023.

Stuck at the bedside: the answer exists, but finding it takes too long.

Medwise ai in Leeds gives clinicians a quick way to search trusted guidance, local NHS protocols and drug information. It says the platform is used across more than 2,000 NHS organisations.

Curious where others think the biggest delay is: finding good drug candidates, proving they work, or getting information to the people treating patients?

Sign In or Register to comment.